Robert A. Sikes
Robert A. Sikes
Office: 326 Wolf Hall
Lab: 334 Wolf Hall
Resources and Links
Education
- B.A. - University of Colorado
- Ph.D. - University of Texas
- Postdoctoral - University of Texas, Health Science Center
- Postdoctoral - University of Texas, M.D. Anderson Cancer Center
Teaching
- BISC 205 - Introductory Biology for the Health Sciences
- BISC 401 - Molecular Biology of the Cell
- BISC602- Advanced Molecular Biology of the Animal Cell
Research Interests
The "Lethal Phenotype" of cancer is a direct consequence of cancer spreading to secondary sites, a process called metastasis. Lethal prostate cancer is no exception. The number of men affected by prostate cancer is staggering. In North America, there are approximately 165,000 new cases of prostate cancer in 2018 and around 29,480 deaths (unchanged since 2014). This translates into a 1 in 9 lifetime chance of acquiring an invasive prostate cancer if you are an American male. This translates into ~19 new cases of prostate cancer diagnosed every hour of every day, day after day. With a decreased reliance upon PSA testing the number of prostate cancers detected has dropped significantly; however, the deaths from the disease remain unchanged. These numbers are going to increase as our population ages.
Current Projects
- IGF and TGFβ in prostate cancer progression and the colonization of bone - By mediating the mesenchymal transition of prostate cancer cells, TGFβ influences cell adhesion to and extravasation through endothelial cells. The signaling mediating this process is poorly understood. We now believe that these events are mediated in part by Smad independent signaling involving Rho GTPases. IGF1 is a survival factor for prostate cancer and appears o play a critical role in the survival of prostate cancer in the bone. We are examining receptor blockade to interfere with this process.
Research Group
- Jordan Shaver- GRA- Cellular interaction between bone marrow stromal cells and prostate cancer